• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌患者根据淋巴结转移情况的生存率:聚焦唾液

Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva.

作者信息

Bel'skaya Lyudmila V, Sarf Elena A, Kosenok Victor K

机构信息

Biochemistry Research Laboratory, Omsk State Pedagogical University, 644099 Omsk, Russia.

Department of Oncology, Omsk State Medical University, 644099 Omsk, Russia.

出版信息

Diagnostics (Basel). 2021 May 20;11(5):912. doi: 10.3390/diagnostics11050912.

DOI:10.3390/diagnostics11050912
PMID:34065406
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8161301/
Abstract

The aim of this study was to compare overall survival (OS) rates at different pN stages of NSCLC depending on tumor characteristics and to assess the applicability of saliva biochemical markers as prognostic signs. The study included 239 patients with NSCLC (pN-120, pN-51, pN-68). Saliva was analyzed for 34 biochemical indicators before the start of treatment. For pN, the tumor size does not have a prognostic effect, but the histological type should be taken into account. For pN and pN, long-term results are significantly worse in squamous cell cancer with a large tumor size. A larger volume of surgical treatment reduces the differences between OS. The statistically significant factors of an unfavorable prognosis at pN are the lactate dehydrogenase activity <1294 U/L and the level of diene conjugates >3.97 c.u. (HR = 3.48, 95% CI 1.21-9.85, = 0.01541); at pN, the content of imidazole compounds >0.296 mmol/L (HR = 6.75, 95% CI 1.28-34.57, = 0.00822); at pN levels of protein <0.583 g/L and Schiff bases >0.602 c.u., as well as protein >0.583 g/L and Schiff bases <0.602 c.u. (HR = 2.07, 95% CI 1.47-8.93, = 0.04351). Using salivary biochemical indicators, it is possible to carry out stratification into prognostic groups depending on the lymph node metastasis.

摘要

本研究的目的是根据肿瘤特征比较非小细胞肺癌(NSCLC)不同pN分期的总生存率(OS),并评估唾液生化标志物作为预后指标的适用性。该研究纳入了239例NSCLC患者(pN- 120例、pN- 51例、pN- 68例)。在治疗开始前对唾液进行了34种生化指标分析。对于pN,肿瘤大小没有预后影响,但应考虑组织学类型。对于pN和pN,肿瘤体积大的鳞状细胞癌的长期结果明显更差。更大范围的手术治疗可缩小OS之间的差异。pN预后不良的统计学显著因素是乳酸脱氢酶活性<1294 U/L和二烯共轭物水平>3.97 c.u.(HR = 3.48,95%CI 1.21 - 9.85,P = 0.01541);对于pN,咪唑化合物含量>0.296 mmol/L(HR = 6.75,95%CI 1.28 - 34.57,P = 0.00822);对于pN,蛋白质水平<0.583 g/L和席夫碱>0.602 c.u.,以及蛋白质>0.583 g/L和席夫碱<0.602 c.u.(HR = 2.07,95%CI 1.47 - 8.93,P = 0.04351)。利用唾液生化指标,可以根据淋巴结转移情况将患者分层为不同的预后组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cf1/8161301/73f742628a2f/diagnostics-11-00912-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cf1/8161301/fe5e7a0aef93/diagnostics-11-00912-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cf1/8161301/73f742628a2f/diagnostics-11-00912-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cf1/8161301/fe5e7a0aef93/diagnostics-11-00912-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cf1/8161301/73f742628a2f/diagnostics-11-00912-g002.jpg

相似文献

1
Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva.非小细胞肺癌患者根据淋巴结转移情况的生存率:聚焦唾液
Diagnostics (Basel). 2021 May 20;11(5):912. doi: 10.3390/diagnostics11050912.
2
Clinical and economic outcomes associated with lymph node examination status in early-stage non-small cell lung cancer: a real-world US study using the SEER-Medicare linked database.早期非小细胞肺癌淋巴结检查状态相关的临床和经济结局:一项使用SEER-医疗保险链接数据库的美国真实世界研究
Transl Cancer Res. 2024 Apr 30;13(4):1821-1833. doi: 10.21037/tcr-23-1388. Epub 2024 Apr 10.
3
Metastasis to subsegmental and segmental lymph nodes in patients resected for non-small cell lung cancer: prognostic impact.非小细胞肺癌患者切除术后亚段和段淋巴结转移:预后影响。
Ann Thorac Surg. 2014 Mar;97(3):987-92. doi: 10.1016/j.athoracsur.2013.11.051. Epub 2014 Jan 28.
4
Combining node location and node ratio as a prognostic factor for surgical resected non-small cell lung cancer: a population-based study.结合淋巴结位置和淋巴结比率作为手术切除的非小细胞肺癌的预后因素:一项基于人群的研究。
J Thorac Dis. 2020 Jul;12(7):3549-3560. doi: 10.21037/jtd-20-758.
5
Prognostic implication of metastasis limited to segmental (level 13) and/or subsegmental (level 14) lymph nodes in patients with surgically resected nonsmall cell lung carcinoma and pathologic N1 lymph node status.手术切除的非小细胞肺癌患者中,病理性 N1 淋巴结状态下,转移仅限于节段性(水平 13)和/或亚节段性(水平 14)淋巴结的预后意义。
Cancer. 2012 Sep 15;118(18):4512-8. doi: 10.1002/cncr.27424. Epub 2012 Jan 26.
6
A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer.非小细胞肺癌淋巴结分类中淋巴结比例与阳性淋巴结解剖位置联合应用的建议。
J Thorac Oncol. 2016 Sep;11(9):1565-73. doi: 10.1016/j.jtho.2016.05.004. Epub 2016 May 17.
7
A proposal for combination of total number and anatomical location of involved lymph nodes for nodal classification in non-small cell lung cancer.提出一种非小细胞肺癌淋巴结分类的方法,即结合淋巴结总数和受累淋巴结的解剖位置。
Chest. 2013 Jun;143(6):1618-1625. doi: 10.1378/chest.12-0750.
8
Prognostic impact of node involvement pattern in pN1 non-small cell lung cancer patients.pN1 期非小细胞肺癌患者淋巴结受累模式的预后影响。
J Thorac Oncol. 2010 Oct;5(10):1576-82. doi: 10.1097/JTO.0b013e3181ec7e70.
9
Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.诱导治疗后纵隔降期并非选择能从手术中获益患者的重要预后因素:淋巴结比率的临床价值
Interact Cardiovasc Thorac Surg. 2015 Feb;20(2):222-7. doi: 10.1093/icvts/ivu378. Epub 2014 Nov 20.
10
[Prognostic factors of lymph node-negative metastasis gastric cancer].[淋巴结阴性转移性胃癌的预后因素]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Feb 25;20(2):190-194.

引用本文的文献

1
Identification of Metastatic Lymph Nodes Using Indocyanine Green Fluorescence Imaging.使用吲哚菁绿荧光成像识别转移性淋巴结
Cancers (Basel). 2023 Mar 25;15(7):1964. doi: 10.3390/cancers15071964.
2
Diagnostic Efficacy of CT Examination on Early Detection of Lung Cancer during Pandemic of COVID-19.CT检查在COVID-19大流行期间早期检测肺癌的诊断效能
Diagnostics (Basel). 2022 Sep 26;12(10):2317. doi: 10.3390/diagnostics12102317.
3
Prognostic Value of Salivary Biochemical Indicators in Primary Resectable Breast Cancer.唾液生化指标在原发性可切除乳腺癌中的预后价值

本文引用的文献

1
Prognostic effect of incongruous lymph node status in early-stage non-small cell lung cancer.早期非小细胞肺癌中淋巴结状态不一致的预后影响。
Eur J Surg Oncol. 2021 Feb;47(2):450-455. doi: 10.1016/j.ejso.2020.06.003. Epub 2020 Jun 10.
2
Independent risk factors for lymph node metastasis in 2623 patients with Non-Small cell lung cancer.2623 例非小细胞肺癌患者淋巴结转移的独立危险因素。
Surg Oncol. 2020 Sep;34:256-260. doi: 10.1016/j.suronc.2020.05.005. Epub 2020 May 22.
3
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Metabolites. 2022 Jun 16;12(6):552. doi: 10.3390/metabo12060552.
4
Application of Non-Blood-Derived Fluid Biopsy in Monitoring Minimal Residual Diseases of Lung Cancer.非血液来源的液体活检在监测肺癌微小残留病中的应用。
Front Surg. 2022 May 16;9:865040. doi: 10.3389/fsurg.2022.865040. eCollection 2022.
可溶性PD-L1以及循环CD8+PD-1+和NK细胞构成免疫治疗的非小细胞肺癌患者的预后和预测性免疫效应评分。
Lung Cancer. 2020 Oct;148:1-11. doi: 10.1016/j.lungcan.2020.07.028. Epub 2020 Aug 2.
4
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.EPSILoN:免疫治疗晚期非小细胞肺癌中使用临床和血液生物标志物的预后评分。
Clin Lung Cancer. 2020 Jul;21(4):365-377.e5. doi: 10.1016/j.cllc.2019.11.017. Epub 2020 Mar 7.
5
Biochemical Markers of Saliva in Lung Cancer: Diagnostic and Prognostic Perspectives.肺癌唾液中的生化标志物:诊断与预后视角
Diagnostics (Basel). 2020 Mar 27;10(4):186. doi: 10.3390/diagnostics10040186.
6
Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients.6101 例非小细胞肺癌患者的生存情况及组织学预后因素分析。
Respir Med Res. 2020 Mar;77:46-54. doi: 10.1016/j.resmer.2019.10.001. Epub 2019 Oct 28.
7
Survival disparities following surgery among patients with different histological types of non-small cell lung cancer.不同组织学类型非小细胞肺癌患者手术后的生存差异。
Lung Cancer. 2020 Feb;140:55-58. doi: 10.1016/j.lungcan.2019.12.007. Epub 2019 Dec 17.
8
Prognostic Impact of the Number of Metastatic Lymph Nodes on the Eighth Edition of the TNM Classification of NSCLC.转移性淋巴结数量对第八版 NSCLC TNM 分类的预后影响。
J Thorac Oncol. 2019 Aug;14(8):1408-1418. doi: 10.1016/j.jtho.2019.04.016. Epub 2019 May 2.
9
[Correlation interrelations between the composition of saliva and blood plasmain norm.].[正常情况下唾液与血浆成分之间的相互关系。]
Klin Lab Diagn. 2018;63(8):477-482. doi: 10.18821/0869-2084-2018-63-8-477-482.
10
Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer.血清循环游离DNA作为非小细胞肺癌潜在的诊断和预后生物标志物。
Biochem Biophys Rep. 2018 Jun 30;15:45-51. doi: 10.1016/j.bbrep.2018.06.002. eCollection 2018 Sep.